Journal article · 2026 · Open access

A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database

Fenja Klima, Thomas Helland, Robin Michelet, Anna M. Mc Laughlin, Jesse Joachim Swen, Henk‐Jan Guchelaar, Fabienne Thomas, Mélanie White‐Koning, Ron H. N. van Schaik, Ron H.J. Mathijssen, Werner Schroth, Matthias Georg Schwab and 4 more

Clinical Pharmacology & Therapeutics · Published 11 November 2026 · DOI 10.1002/cpt.70560

Open full textCite this paper

In brief

“A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database” is a 2026 journal article by Fenja Klima and 15 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
49
Authors
16

Abstract

The polymorphic enzyme CYP2D6 contributes to the metabolism of many frequently prescribed drugs, causing substantial variability in drug exposure and treatment outcomes. Genotype-based dosing recommendations currently rely on drug-agnostic categorical CYP2D6 allele activity values (AVs), potentially leading to imprecise CYP2D6 phenotype classification and under-/overdosing of numerous medications. To further advance precision dosing, we developed a CYP2D6 percentage activity (CYP2D6-PA) framework by estimating CYP2D6 allelic percentage activity (CYP2D6-APA) from 0% (no activity) to 100% (CYP2D6*1-normalized reference activity) using tamoxifen and its active metabolite Z-endoxifen as a model substrate. By leveraging nonlinear mixed-effects modeling of the international CEPAM database (>7,000 patients from 31 studies), bias-corrected CYP2D6-APAs were estimated, considering global allele distributions, additional covariates, and limited CYP2D6 genotyping. Estimated CYP2D6-APAs spanned 0%-100%, several deviating substantially from their categorical AVs. In particular, CYP2D6*2 and *35 (normal function, AV = 1), and *17 and *29 (decreased function, AV = 0.5) showed lower CYP2D6-APAs of 64-68% and 29%, respectively. Conversely, CYP2D6*9 (decreased function, AV = 0.25) showed a higher CYP2D6-APA (52%). Each additional allele copy exhibited 68% of the activity of the first copy, less than the twofold increase assumed by AVs. Neglecting limited genotyping (alleles misclassified as reference CYP2D6*1), caused CYP2D6-APA overestimation by 1.1-fold. Using CYP2D6-APAs instead of AVs translated to changes in predicted individual Z-endoxifen concentrations (-22.3% to 40.0%). While substrate specificity of empirically derived robust tamoxifen CYP2D6-APAs requires evaluation, CYP2D6-PA provides a framework applicable to other substrates/pharmacogenes. Thus, CYP2D6-PA lays the foundation for revising genotype-to-phenotype translation systems, improving precision of pharmacogenetics-guided dosing and optimizing treatment outcomes upon prospective validation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Klima, F., Helland, T., Michelet, R., Laughlin, A. M. M., Swen, J. J., Guchelaar, H., Thomas, F., White‐Koning, M., van Schaik, R. H. N., Mathijssen, R. H., Schroth, W., Schwab, M. G., Mellgren, G., Gaedigk, A., Hertz, D. L., & Kloft, C. (2026). A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70560

MLA 9

Klima, Fenja, et al. “A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70560.

Chicago

Klima, Fenja, Thomas Helland, Robin Michelet, Anna M. Mc Laughlin, Jesse Joachim Swen, Henk‐Jan Guchelaar, Fabienne Thomas, et al. 2026. “A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70560.

Harvard

Klima, F. et al. (2026) ‘A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70560.

IEEE

F. Klima et al., “A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70560.

BibTeX

@article{klima2026precise,
  title     = {{A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database}},
  author    = {Klima, Fenja and Helland, Thomas and Michelet, Robin and Laughlin, Anna M. Mc and Swen, Jesse Joachim and Guchelaar, Henk‐Jan and Thomas, Fabienne and White‐Koning, Mélanie and van Schaik, Ron H. N. and Mathijssen, Ron H.J. and Schroth, Werner and Schwab, Matthias Georg and Mellgren, Gunnar and Gaedigk, Andrea and Hertz, Daniel L. and Kloft, Charlotte},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70560},
  url       = {https://doi.org/10.1002/cpt.70560}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • CYP2D6
  • CYP2D6*17
  • tamoxifen
  • Z-endoxifen
  • precision dosing
  • genotype-based dosing
  • nonlinear mixed-effects models
  • drug metabolism variability

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Klima, F., Helland, T., Michelet, R., Laughlin, A. M. M., Swen, J. J., Guchelaar, H., Thomas, F., White‐Koning, M., van Schaik, R. H. N., Mathijssen, R. H., Schroth, W., Schwab, M. G., Mellgren, G., Gaedigk, A., Hertz, D. L., & Kloft, C. (2026). A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM Database. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70560

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the full text from this page.

Who wrote this paper?

Fenja Klima, Thomas Helland, Robin Michelet, Anna M. Mc Laughlin, Jesse Joachim Swen, Henk‐Jan Guchelaar, Fabienne Thomas, Mélanie White‐Koning, Ron H. N. van Schaik, Ron H.J. Mathijssen, Werner Schroth, Matthias Georg Schwab and 4 more.

What is the DOI of this paper?

10.1002/cpt.70560, permanently at https://doi.org/10.1002/cpt.70560. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.